PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18794388-3	2008	METHODS AND RESULTS: Antisense oligonucleotides were used to inhibit SCD1 in a mouse model of hyperlipidemia and atherosclerosis (LDLr(-/-)Apob(100/100)).	Oligonucleotides	31-47	stearoyl-Coenzyme A desaturase 1	Mus musculus	69-73	
18832746-7	2008	In mice exposed to CIH and treated with SCD-1 antisense oligonucleotides, dyslipidemia and atherosclerosis in the ascending aorta were abolished, whereas lesions in the descending aorta showed 56% reduction.	Oligonucleotides	56-72	stearoyl-Coenzyme A desaturase 1	Mus musculus	40-45	
16741573-4	2006	This commentary focuses on 2 recent studies published in the JCI that address this question using antisense oligonucleotide inhibition of SCD1.	Oligonucleotides	108-123	stearoyl-Coenzyme A desaturase 1	Mus musculus	138-142	
15761499-0	2005	Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1.	Oligonucleotides	43-58	stearoyl-Coenzyme A desaturase 1	Mus musculus	73-98	
15761499-4	2005	SCD1-specific antisense oligonucleotide inhibitors (ASOs) reduced SCD1 expression, reduced fatty acid synthesis and secretion, and increased fatty acid oxidization in primary mouse hepatocytes.	Oligonucleotides	24-39	stearoyl-Coenzyme A desaturase 1	Mus musculus	0-4	
15761499-4	2005	SCD1-specific antisense oligonucleotide inhibitors (ASOs) reduced SCD1 expression, reduced fatty acid synthesis and secretion, and increased fatty acid oxidization in primary mouse hepatocytes.	Oligonucleotides	24-39	stearoyl-Coenzyme A desaturase 1	Mus musculus	66-70